U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07173686) titled 'Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy' on Sept. 08.
Brief Summary: Diabetic kidney disease (DKD) is one of the most common microvascular complications of type 2 diabetes mellitus (T2DM), affecting up to 40% of diabetic patients and accounting for the leading cause of end-stage renal disease worldwide [1]. The progression of DKD involves multiple mechanisms, including oxidative stress, endothelial dysfunction, and most importantly, chronic inflammation [2].
Systemic inflammation plays a central role in renal injury by promoting glomerular and tubulointerstitial damage. t...